Loading
Life sciences · Phase 1 Trial
ClinicalTrials.gov · October 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07873645). This is a study registration, not published results. Lead sponsor: The United Bio-Technology (Hengqin) Co., Ltd.. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 40 participants (ESTIMATED). Conditions: Overweight , Obesity. Interventions: DRUG: UBT37034; DRUG: Placebo. Primary outcome measures: Incidence of Adverse Events (AEs) , Baseline to Week23; Change from baseline in physical examinations , Baseline to Week 23; Change from baseline in body temperature , Baseline to Week 23; Change from baseline in pulse rate , Baseline to Week 23; Change from baseline in blood pressure , Baseline to Week 23; Change from baseline in ECG QTcF interval , Baseline to Week 23; Change from baseline in ECG RR interval , Baseline to Week 23; Change from baseline in ECG heart rate , Baseline to Week 23; Change from baseline in PHQ-9 total score , Baseline to Week 23; Change from baseline in C-SSRS score , Baseline to Week 23. Brief summary: This is a study of UBT37034 for injection in participants who have obesity or are overweight. The main purpose is to learn more about the safety, tolerability, drug concentration, drug action and immune response of repeated UBT37034 administration. This is a single-center, randomized, double-blind, placebo-controlled study with multiple ascending doses. A total of 40 participants will be enrolled in 4 different dose groups. Participants will receive UBT37034 or placebo in an 8:2 random ratio with dose titration. The study will last up to 24 weeks and includes screening, treatment and safety follow-up periods.